Author’s response to reviews

Title: Doxycycline for the treatment of nodding syndrome (DONS): a phase II, randomised placebo controlled trial. The study protocol

Authors:

Richard Idro (ridro1@gmail.com)
Ronald Anguzu (ranguzu@musph.ac.ug)
Rodney Ogwang (rjogwang@gmail.com)
Pamela Akun (pamakun@gmail.com)
Catherine Abbo (cathya180@gmail.com)
Amos Mwaka (mwakaad@yahoo.com)
Bernard Opar (bopato@gmail.com)
Phyellister Nakamya (phellister@gmail.com)
Mark Taylor (Mark.Taylor@lstmed.ac.uk)
Alison Elliot (Alison.Elliott@mrcuganda.org)
Angela Vincent (angela.vincent@ndcn.ox.ac.uk)
Charles Newton (CNewton@kemri-wellcome.org)
Kevin Marsh (kevin.marsh@ndm.ox.ac.uk)

Version: 3 Date: 13 Dec 2018

Author’s response to reviews:

Response to Reviewers and Editors Comments

13 December 2018
Dear Editor

Please find herein our response to the queries you raised.

1) Thank you forwarding additional documentation. However, the documentation you have provided pertains again to the peer review reports from the MRC prior to a funding decision. Please provide a copy of the original (and endorsed) documentation from the MRC which details that funding approval for your study has been obtained, and which describes the funding terms. These documents should be sent as email attachments to the following email address, BMCSeriesEditorial@biomedcentral.com. Please DO NOT upload these documents as additional files in the submission system.

This document has been emailed as requested to BMCSeriesEditorial@biomedcentral.com

2) Please ensure that the trial registration date, registry name and the trial registration number are appended to the Trial Registration section at the end of the Abstract in the online submission field.

This has been done.

3) Please integrate the Study Acronym within the manuscript title.

This has been incorporated.

4) Please remove the word count from the manuscript abstract.

Removed.
5) Please remove the protocol version information below the manuscript abstract.

Removed.

6) Please remove the ‘BMC Neurology’ page header throughout the manuscript.

Removed.

7) Please expand on the strengths and limitations of your proposed study in the Discussion section of the manuscript.

We have added one paragraph of strengths and limitations at the end of the discussion.

8) Please remove the trial status section following the Discussion.

Removed.

9) Please rename ethical considerations to ‘the Ethics approval and consent to participate’.

This has been renamed.

10) If your manuscript does not contain data from any individual person, please state “Not applicable” in the Consent for publication section of the Declarations.

Done
11) Please remove the SPIRIT checklist attached to the manuscript as this was for our Editorial records.

Removed.

12) At this stage, please upload your manuscript as a single, final, clean version that does not contain any tracked changes, comments, highlights, strikethroughs or text in different colours. All relevant tables/figures/additional files should also be clean versions. Figures (and additional files) should remain uploaded as separate files.

Uploaded as such.

Thank you

Dr Richard Idro